Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) Equity Average (2020 - 2025)

Historic Equity Average for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $1.0 billion.

  • Legend Biotech's Equity Average fell 1003.51% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 1003.51%. This contributed to the annual value of $1.1 billion for FY2024, which is 1484.37% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Equity Average is $1.0 billion, which was down 1003.51% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Equity Average peaked at $1.4 billion during Q3 2023, and registered a low of $273185.0 during Q2 2021.
  • Its 5-year average for Equity Average is $857.7 million, with a median of $1.0 billion in 2025.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 3063863.45% in 2021, then plummeted by 1716.84% in 2024.
  • Quarter analysis of 5 years shows Legend Biotech's Equity Average stood at $495.9 million in 2021, then soared by 51.95% to $753.6 million in 2022, then soared by 71.92% to $1.3 billion in 2023, then decreased by 16.76% to $1.1 billion in 2024, then decreased by 5.09% to $1.0 billion in 2025.
  • Its Equity Average stands at $1.0 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.0 billion for Q1 2025.